NIOSHTIC-2 Publications Search

Quantification of regional glial fibrillary acidic protein levels in Alzheimer's disease.

Ross GW; O'Callaghan JP; Sharp DS; Petrovich H; Miller DB; Abbott RD; Nelson J; Launer LJ; Foley DJ; Burchfiel CM; Hardman J; White LR

Acta Neurol Scand 2003 May; 107(5):318-323

https://doi.org/10.1034/j.1600-0404.2003.02098.x

20023023

Our objectives were to quantify glial fibrillary acidic protein (GFAP) in brains of Alzheimer's disease (AD) cases, and non-AD controls to determine the regions with the most severe gliosis in AD. In a case control design, we used an enzyme-linked immunosorbent assay (ELISA) to quantify GFAP in frozen brain from four areas of neocortex in 10 AD cases, 10 age-matched controls, and 10 younger controls from the Honolulu-Asia Aging Study autopsy archive. Median age at death was 83.5 years for cases and age-matched controls, and 77 years for younger controls. For the AD cases compared with the age-matched controls, levels of GFAP in occipital (P=0.01), parietal (P=0.028), and temporal lobes (P=0.004) (but not frontal) were significantly higher in the cases. The median GFAP excess in AD cases compared with age matched controls was highest in the temporal lobe. Regional quantification of GFAP reveals that the glial response is most prominent in the temporal lobe in AD.

Brain-disorders; Brain-function; Humans; Autopsies; Mortality-data; Mortality-surveys; Author Keywords: Gliosis; Alzheimer disease; dementia; glial fibrillary acidic protein

G. Webster Ross, Pacific Health Research Institute, Suite 307, 846 South Hotel Street, Honolulu, HI 90813

ANRSAS

20030501

Journal Article

ross@phri.hawaii-health.com

2003

5

0001-6314

HELD

Work Environment and Workforce: Special Populations

Acta Neurologica Scandinavica

HI; WV; VA; MD